What question did this study set out to answer?

Abstract MPTH69: Metabolic Dysfunction-Associated Steatotic Liver Disease Across the Cardiovascular-Kidney-Metabolic Spectrum: Insights from the CARDIA Study

View Full Paper

Ask AI

Bookmark

Authors

Prospective study shows metabolic dysfunction-associated steatotic liver disease increases long-term adverse outcomes and cardiovascular events.

To evaluate the prevalence and impact of metabolic dysfunction-associated steatotic liver disease across the cardiovascular-kidney-metabolic spectrum.
Conducted a prospective study using the CARDIA cohort.
Performed abdominal computed tomography on participants.
Defined MASLD by hepatic steatosis and cardiometabolic criteria.
Conducted subgroup analyses based on CKM stage.
24% of participants had MASLD, increasing prevalence with higher CKM stages.
MASLD associated with a higher incidence of all-cause death and cardiovascular events.
After adjustments, MASLD correlated with significant long-term adverse outcomes.

Ostrominski et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Prospective study shows metabolic dysfunction-associated steatotic liver disease increases long-term adverse outcomes and cardiovascular events.

To evaluate the prevalence and impact of metabolic dysfunction-associated steatotic liver disease across the cardiovascular-kidney-metabolic spectrum.
Conducted a prospective study using the CARDIA cohort.
Performed abdominal computed tomography on participants.
Defined MASLD by hepatic steatosis and cardiometabolic criteria.
Conducted subgroup analyses based on CKM stage.
24% of participants had MASLD, increasing prevalence with higher CKM stages.
MASLD associated with a higher incidence of all-cause death and cardiovascular events.
After adjustments, MASLD correlated with significant long-term adverse outcomes.

Ostrominski et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark